Ficlatuzumab

Ficlatuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	HGF
Clinical data
ATC code	none;
Identifiers
CAS Number	1174900-84-5 ;
ChemSpider	none;
UNII	77E89833TG;
KEGG	D10123 ;
Chemical and physical data
Formula	C6446H9954N1718O2026S46
Molar mass	145409.30 g·mol−1
	(what is this?) (verify)

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.^[1]

It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.^[2]

Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.^[3]

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
^ Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. pp. 49–64 (57). doi:10.1007/978-3-030-55035-6_3. ISBN 978-3-030-55034-9. PMID 33725344. S2CID 232261340.
^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Ficlatuzumab
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.

[pmid33725344-2] Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. pp. 49–64 (57). doi:10.1007/978-3-030-55035-6_3. ISBN 978-3-030-55034-9. PMID 33725344. S2CID 232261340.

[3] "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012

[1]

[2]

[3]